PL1608346T3 - Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania - Google Patents

Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania

Info

Publication number
PL1608346T3
PL1608346T3 PL04759681T PL04759681T PL1608346T3 PL 1608346 T3 PL1608346 T3 PL 1608346T3 PL 04759681 T PL04759681 T PL 04759681T PL 04759681 T PL04759681 T PL 04759681T PL 1608346 T3 PL1608346 T3 PL 1608346T3
Authority
PL
Poland
Prior art keywords
alpha
acid ester
hydroxy acid
methods
drug delivery
Prior art date
Application number
PL04759681T
Other languages
English (en)
Inventor
John M Lipari
Michelle A Long
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL1608346T3 publication Critical patent/PL1608346T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04759681T 2003-03-31 2004-03-19 Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania PL1608346T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/403,071 US20040191207A1 (en) 2003-03-31 2003-03-31 Alpha-hydroxy acid ester drug delivery compositions and methods of use
PCT/US2004/008417 WO2004093851A1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP04759681A EP1608346B1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
PL1608346T3 true PL1608346T3 (pl) 2009-07-31

Family

ID=32989847

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04759681T PL1608346T3 (pl) 2003-03-31 2004-03-19 Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania

Country Status (14)

Country Link
US (1) US20040191207A1 (pl)
EP (1) EP1608346B1 (pl)
JP (2) JP5005339B2 (pl)
AT (1) ATE413865T1 (pl)
CA (1) CA2518918C (pl)
CY (1) CY1108700T1 (pl)
DE (1) DE602004017705D1 (pl)
DK (1) DK1608346T3 (pl)
ES (1) ES2317017T3 (pl)
MX (1) MXPA05010607A (pl)
PL (1) PL1608346T3 (pl)
PT (1) PT1608346E (pl)
SI (1) SI1608346T1 (pl)
WO (1) WO2004093851A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
DE102010013064A1 (de) 2010-03-26 2011-12-15 Gabriele Blume Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
US20250262183A1 (en) * 2024-02-19 2025-08-21 Harvey Tenenbaum Antibiotic Topical Composition for Absorption into Systemic Bloodstream

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492325A (en) * 1967-03-24 1970-01-27 Procter & Gamble Production of alpha-hydroxy acids and esters
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
CA2185600A1 (en) * 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
EP0999829A1 (en) * 1997-07-01 2000-05-17 Pfizer Products Inc. Solubilized sertraline compositions
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA01011343A (es) * 1999-05-07 2002-06-04 Pharmasol Gmbh Particulas de lipidos a base de mezclas de lipidos liquidos y solidos asi como procedimiento para su produccion.
AU5072000A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for nasally administering water-soluble active substances
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Also Published As

Publication number Publication date
EP1608346A1 (en) 2005-12-28
CA2518918A1 (en) 2004-11-04
PT1608346E (pt) 2009-02-06
EP1608346B1 (en) 2008-11-12
JP5005339B2 (ja) 2012-08-22
JP2012136521A (ja) 2012-07-19
ES2317017T3 (es) 2009-04-16
JP5592905B2 (ja) 2014-09-17
DE602004017705D1 (de) 2008-12-24
ATE413865T1 (de) 2008-11-15
US20040191207A1 (en) 2004-09-30
CA2518918C (en) 2011-08-09
JP2006522105A (ja) 2006-09-28
CY1108700T1 (el) 2014-04-09
MXPA05010607A (es) 2005-11-23
DK1608346T3 (da) 2009-01-26
SI1608346T1 (sl) 2009-04-30
WO2004093851A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
MY161991A (en) Proteasome inhibitors
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
MEP18208A (en) Immune response modifier foam formulations
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
MX349769B (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
GB9800526D0 (en) Organic compounds
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2010033726A3 (en) Drug delivery composition comprising a self-assembled gelator
MX2010005714A (es) Compuestos de piridina.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
ZA200805598B (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
TW200833375A (en) Pharmaceutical compositions
UA95254C2 (ru) Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит
TW200630087A (en) Medicinal composition comprising with lowering blood free fatty acid
WO2007068070A3 (en) Composition containing an inhibitor of phosphodiesterase iii and a therapeutic alcohol for the treatment of atherosclerosis diseases